Solid Biosciences Launches $200 Million At-The-Market Equity Offering Program

On August 6, 2026, Solid Biosciences Inc. filed a prospectus supplement for the offer and sale of up to $200.0 million of its common stock. This offering is conducted through an 'at-the-market' equity program pursuant to an Amended and Restated Sales Agreement with Jefferies LLC, originally dated March 13, 2024. This new filing follows a prior prospectus supplement under which the company successfully sold approximately $85.0 million of common stock. Upon the filing of this new Prospectus Supplement, the company will cease making offers or sales under the previous supplement. The shares are being issued under the company’s existing universal shelf registration statement on Form S-3, which was declared effective by the SEC on May 27, 2025. The proceeds from such sales are typically intended for general corporate purposes, including research and development and working capital. Wilmer Cutler Pickering Hale and Dorr LLP provided the legal opinion regarding the validity of the shares being offered.